Published on in Vol 11, No 7 (2022): July

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/37898, first published .
Intravenous Infusion of Autoserum-Expanded Autologous Mesenchymal Stem Cells in Patients With Chronic Brain Injury: Protocol for a Phase 2 Trial

Intravenous Infusion of Autoserum-Expanded Autologous Mesenchymal Stem Cells in Patients With Chronic Brain Injury: Protocol for a Phase 2 Trial

Intravenous Infusion of Autoserum-Expanded Autologous Mesenchymal Stem Cells in Patients With Chronic Brain Injury: Protocol for a Phase 2 Trial

Journals

  1. Yamaki T, Oka S, Iyama S, Sasaki M, Onodera R, Kataoka-Sasaki Y, Namioka T, Namioka A, Nakazaki M, Takemura M, Ukai R, Yokoyama T, Sasaki Y, Yamashita T, Kobayashi M, Yamaguchi M, Fukino M, Takazawa T, Hayasaka M, Owaku T, Funakura M, Onodera S, Ito Y, Kobune M, Kato J, Ishiai S, Kocsis J, Odaki M, Iwadate Y, Kobayashi S, Honmou O. Intravenous infusion of auto-serum-expanded autologous mesenchymal stem cells into chronic severe brain injury patients. Interdisciplinary Neurosurgery 2024;36:101927 View
  2. Tashima T. Mesenchymal Stem Cell (MSC)-Based Drug Delivery into the Brain across the Blood–Brain Barrier. Pharmaceutics 2024;16(2):289 View
  3. Liu L, Lin Z, Yang J. The Preclinical and Clinical Applications of Mesenchymal Stem Cells in Stroke. International Journal of Pharmaceutical Research and Allied Sciences 2023;12(4):118 View

Books/Policy Documents

  1. Muresanu D, Sharma A, Tian Z, Lafuente J, Nozari A, Feng L, Buzoianu A, Wiklund L, Sharma H. Progress in Nanomedicine in Neurologic Diseases. View